Coral Laboratories share price, P/E, ROE & financials

Coral Laboratories (BSE: CORALAB) had a P/E of 9.3× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 27% below their 52-week high. Its ROCE of 11% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 2.7% and 36% a year over 3 years. It has almost no debt, and its dividend yield is 0.4%. It is a small-cap company with a market cap of ₹178 Cr, ranked 100th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 0.1% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹499.80
Day high: ₹504.00
Day low: ₹478.00
Prev. close: ₹494.85
Volume: 338

Health check

1 good · 2 fair · 3 to check

ReturnsBehind
+0.1% over a year, better than 1 of 7 peers.
Price tagCheaper
P/E 9.3 vs industry 28.7.
GrowthSteady
Sales +2.7%, profit +36.5% a year over 3 years.
ProfitabilityWeak
ROCE 10.9% vs peer median 17.9%.
Balance sheetFair
Practically debt-free, Piotroski 4 of 9.
Red flags1 to check
Return on equity is low at 8.0%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹178 Cr, #100 of 154 in its industry by size.

Moves with the market

Beta 0.85 vs the NIFTY 50: tracks the market closely.

Key metrics

Last 12 months to Jun 2026: sales ₹97 Cr · profit ₹19 Cr

Market cap: ₹178 Cr; Small cap
P/E: 9.3; Industry 28.7
Price to book: 0.85; Peers 4.99
Dividend yield: 0.40%
ROE: 8.0%; Peers 14.7%
ROCE: 10.9%; Peers 17.9%
Debt to equity: 0.02; Debt ₹4.33 Cr
EPS (TTM): ₹53.76
OPM (TTM): 19.2%; Net margin 19.9%
Sales growth: +57.4%; Latest quarter vs a year ago
Profit growth: +110.1%; Latest quarter vs a year ago
Price to sales: 1.84; EV/EBITDA 4.4

Strengths

Practically debt-free.
Quarterly profit up 110.1% on a year ago.
Quarterly sales up 57.4% on a year ago.
P/E of 9.3 against an industry P/E of 28.7.

Risks to check

Return on equity is low at 8.0%.

Derived automatically from reported figures. Not a recommendation.

About Coral Laboratories

Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethiopia, and internationally. The company offers non-sterile products, including antibiotics/antibacterial, antifungal, gastro-intestinal drugs, antiemetic, analgesics/antipyretic/anti-inflammatory, antispasmodic, muscle relaxants, cough suppressant/expectorant, anticold, antiallergic, anti-asthmatic, cardiovascular medicines, anti-diabetic, anthelmentic,…

Headquarters: Mumbai
Employees: 149
Sector: Healthcare
ISIN: INE683E01017
Website: corallab.com

Price range

52 weeks

₹360.00₹679.00

Today

₹478.00₹504.00

Avg volume (3M): 1.5K
1-year return: plus 0.1%
From 52-week high: minus 26.7%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
CORALABCoral Laboratories	498.00	plus 0.64%	178	9.3	0.85	10.9%	8.0%	19.2%	2.7%	36.5%	0.40%	plus 0.1%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
18.8	19	21.6	26.5	29.6
16.6	14.1	19.7	20.3	24.1
2.2	4.9	1.9	6.2	5.5
11.6%	25.9%	8.8%	23.4%	18.5%
2	2.7	2.5	2.6	2.2
0.1	0.1	0	0	0
0.5	0.5	0.7	0.5	0.7
–	0.3	–	−0	–
3.7	7.4	3.7	8.3	6.9
31.1%	21.5%	24.9%	37.0%	22.4%
2.6	5.8	2.8	5.2	5.4
7.18	16.29	7.77	14.62	15.08

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +2.7%
Profit CAGR 3Y: +36.5%
EPS CAGR 3Y: +36.5%
ROE: 8.0%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
77.9	82.1	113	84.4
–	+5.4%	+37.9%	minus 25.4%
74.1	65.9	86.6	69
3.8	16.2	26.6	15.3
4.9%	19.8%	23.5%	18.2%
6.9	6.6	8.7	9.8
0.3	0	0.1	0.2
2.2	2	2	2.1
0	−0.2	−0.8	0.3
8.2	20.7	32.5	23.1
21.6%	23.8%	25.6%	29.1%
6.4	15.8	24.2	16.4
–	+145.0%	+53.0%	minus 32.2%
18.04	44.19	67.61	45.85

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
3.6	3.6	3.6	3.6
151	174	198	206
–	–	3.6	4.3
19.5	28.2	24.7	27.2
174	206	229	241
24.3	23.3	24.2	43.2
–	0	2.5	0
17.4	24	24.8	16.8
30	27.8	107	30.7
103	131	70.5	150
174	206	229	241

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
12.7	−5.5	−1.2	15.6
−2.6	1.4	−0.2	−17.7
−6.4	0	2.7	0.1
3.6	−4.1	1.3	−2
−1.9	−1	−2.9	−23.5
10.7	−6.5	−4.2	−7.9
–	–	−0.7	−0.5

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you